Drugs / APG-1387
APG-1387
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03585322 | Jul 2018 → Oct 2021 | chronic hepatitis B virus infection | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03386526 | Nov 2017 → Oct 2022 | neoplasm | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04643405 | Mar 2021 → Jun 2024 | pancreatic adenocarcinoma | Ascentage Pharma Group Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04284488 | Apr 2020 → Nov 2024 | neoplasm | Ascentage Pharma Group Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04568265 | Jun 2020 → Oct 2022 | chronic hepatitis B virus infection | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APG-1387 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04284488 ↗ |
| Known as | APG-1387 (SMAC MIMETIC) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594459 ↗ |
| Known as | SM-1387 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594459 ↗ |
| Action | Inhibit | “APG-1387 is a novel second mitochondria-derived activator of caspase (Smac) mimetic IAP inhibitor.” PMID 38790057 ↗ May 2024 |
| Modality | Small molecule | “APG-1387 is a potent, bivalent small-molecule Inhibitor of Apoptosis Protein (IAP) antagonist.” NCT03386526 ↗ |
| Route | Intravenous | “30 minute IV infusion” NCT03386526 ↗ |